The company had received approval from the Drugs Controller General of India to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms.
In August, the company launched 200 mg Favipiravir tablets. “We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis… introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers,” BDR PharmaCMD Dharmesh Shah said.
The companyhad received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment